Aegerion Pharmaceuticals to Announce First Quarter 2013 Financial Results on Tuesday, April 30

Tue Apr 16, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130416:nGNXUXNZAa

CAMBRIDGE, Mass., April 16, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.
http://www.globenewswire.com/newsroom/ctr?d=10028461&l=1&a=Aegerion%20Pharmaceuticals%2C%20Inc.&u=http%3A%2F%2Fwww.aegerion.com%2F
 (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of
innovative, life-altering therapies for patients with debilitating, often fatal rare diseases,
announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on
Tuesday, April 30, 2013, to provide a business update and to discuss its first-quarter financial
and operational results.

To listen to the live webcast of the call, please visit the "Investors" section of the Company's
website at www.aegerion.com
http://www.globenewswire.com/newsroom/ctr?d=10028461&l=2&a=www.aegerion.com&u=http%3A%2F%2Fwww.aegerion.com%2F
. Individuals may also participate in the call via telephone by dialing (866) 516-3002 or (760)
298-5082. Interested parties unable to join the live call may access an archived version of the
webcast on Aegerion's website for 14 days following the call.

About Aegerion Pharmaceuticals, Inc.
http://www.globenewswire.com/newsroom/ctr?d=10028461&l=3&a=Aegerion%20Pharmaceuticals%2C%20Inc.&u=http%3A%2F%2Fwww.aegerion.com%2F


Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and
commercialization of innovative, life-altering therapies for patients with debilitating, often
fatal, rare diseases. For more information about the company, please visit www.aegerion.com
http://www.globenewswire.com/newsroom/ctr?d=10028461&l=4&a=www.aegerion.com&u=http%3A%2F%2Fwww.aegerion.com%2F
.

CONTACT: Aegerion Pharmaceuticals, Inc.
         Amanda Murphy, Manager, IR
         857-242-5024

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.